Alkermes, Inc.
Waltham, MA, USA
On Nov. 2, 2022, Alkermes plc announced its intention to explore separation of its oncology assets, including nemvaleukin alfa, IL-12 and IL-18. Alkermes plc intends to create a new, publicly-traded company to develop and commercialize such oncology assets. Referred to herein as "Mural Oncology." Alkermes, Inc., a subsidiary of Alkermes plc, is recruiting the position of Senior Research Associate I/II for Mural Oncology in advance of its establishment as a publicly-traded company on The Nasdaq Stock Market. Position Description: We are seeking to add a skilled formulation and drug product development researcher to join our team. The Senior Research Associate role will have responsibilities supporting developability and formulation on a new oncology program. In addition to early development support this role will have exposure to a late stage Phase 3 asset entering process validation with an opportunity to work on cross-functional analytical and process development teams....